The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Valneva (VALN) stock gained as its chikungunya vaccine receives marketing authorization in the U.K., expanding the single-dose shot's global reach. Read more here.

Valneva’s chikungunya vaccine Ixchiq has been greenlit by the UK’s MHRA, allowing the single-dose vaccine to be made ...

Shares of Valneva (VALN), a specialty vaccine company closed up over $1.00 per share or almost 19% to close the regular session at $6.67 per ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

Valneva has recieved Medicines and Healthcare products Regulatory Agency (MHRA) authorisation in the UK for the world’s first - and only - Chikungunya vaccine, IXCHIQ. The single-dose vaccine is ...

UK MHRA grants marketing authorization to Valneva’s chikungunya vaccine, Ixchiq: Saint Herblain, France Thursday, February 6, 2025, 12:00 Hrs [IST] Valneva SE, a specialty vacci ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and ...

French biotech Valneva has secured marketing approval in the UK for its chikungunya vaccine, Ixchiq (chikungunya vaccine), ...

The single-dose vaccine is indicated for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older. The vaccine is manufactured at ...